RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex
- 13 August 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 32 (27), 3263-3273
- https://doi.org/10.1038/onc.2012.337
Abstract
Inhibitor of apoptosis (IAP) proteins represent promising therapeutic targets due to their high expression in many cancers. Here, we report that small-molecule IAP inhibitors at subtoxic concentrations cooperate with monoclonal antibodies against TRAIL receptor 1 (Mapatumumab) or TRAIL-R2 (Lexatumumab) to induce apoptosis in neuroblastoma cells in a highly synergistic manner (combination index <0.1). Importantly, we identify receptor-activating protein 1 (RIP1) as a critical mediator of this synergism. RIP1 is required for the formation of a RIP1/FADD/caspase-8 complex that drives caspase-8 activation, cleavage of Bid into tBid, mitochondrial outer membrane permeabilization, full activation of caspase-3 and caspase-dependent apoptosis. Indeed, knockdown of RIP1 abolishes formation of the RIP1/FADD/caspase-8 complex, caspase activation and apoptosis upon combination treatment. Similarly, inhibition of RIP1 kinase activity by Necrostatin-1 inhibits IAP inhibitor- and TRAIL receptor-triggered apoptosis. In contrast, overexpression of the dominant-negative superrepressor I kappa B alpha-SR or addition of the tumor necrosis factor (TNF)alpha-blocking antibody Enbrel do not interfere with cotreatment-induced apoptosis, pointing to a nuclear factor-kappa B- and TNF alpha-independent mechanism. Of note, IAP inhibitor also sensitizes primary cultured neuroblastoma cells for TRAIL receptor-mediated loss of viability, underscoring the clinical relevance. By identifying RIP1 as a critical mediator of IAP inhibitor- mediated sensitization for Mapatumumab- or Lexatumumab-induced apoptosis, our findings provide new insights into the synergistic interaction of IAP inhibitors together with TRAIL receptor agonists.This publication has 38 references indexed in Scilit:
- cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP IsoformsMolecular Cell, 2011
- Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing programPediatric Blood & Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species productionCell Death & Differentiation, 2010
- Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitmentThe Journal of cell biology, 2009
- Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing programPediatric Blood & Cancer, 2009
- Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-αCell, 2009
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonistsNature Reviews Drug Discovery, 2008
- c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB ActivationOnline Journal of Public Health Informatics, 2008
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007